Can Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Can Chen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ming Yi
Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, P. R. China
1 shared publication - Pengfei Guo
Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, P. R. China
1 shared publication - Shuliang Yang
College of Energy State Key Laboratory of Physical Chemistry of Solid Surfaces Xiamen University Xiamen Fujian China
1 shared publication - Wei Li
Department of Radiology, the Third Xiangya Hospital of Central South University, Changsha, People’s Republic of China
1 shared publication - Wen Liu
Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, P. R. China
1 shared publication - Xiaoqing Jiang
Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, P. R. China
1 shared publication
Latest Publications
- 1 January 2025
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 53 (02) , 597-619
Targeting EGFR-Mcl-1 Axis by Piperlongumine as a Novel Strategy for Non-Small Cell Lung Cancer Therapy
Non-small cell lung cancer (NSCLC) is a malignancy that faces serious resistance challenges in treatment. In this study, we identified Piperlongumine as a promising therapeutic candidate to overcome Osimertinib resistance in NSCLC. We systematically investigated the inhibitory effect of Piperlongumine on NSCLC cells and confirmed that it could effectively inhibit the in vitro kinase activity of wild-type (WT), exon 19 deletion, and L858R/T790M-mutated EGFR. We also found that Piperlongumine-induced intrinsic apoptosis by interfering with the EGFR signaling pathway, which was characterized by the down-regulation of the anti-apoptotic protein Mcl-1. Further mechanistic studies revealed that Piperlongumine-induced degradation of Mcl-1 was dependent on the Akt-GSK3β signaling pathway. Additionally, Piperlongumine-promoted interaction between Mcl-1 and β-TRCP, thereby enhancing β-TRCP-mediated ubiquitination and the degradation of Mcl-1. Furthermore, Piperlongumine significantly inhibited tumor growth in both Osimertinib-sensitive and resistant NSCLC xenograft models. These findings highlight the potential of Piperlongumine as an effective agent in overcoming EGFR-targeted therapy resistance and suggest new avenues for its clinical application in NSCLC treatment.
- 1 January 2025
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 53 (02) , 597-619
Targeting EGFR-Mcl-1 Axis by Piperlongumine as a Novel Strategy for Non-Small Cell Lung Cancer Therapy
Non-small cell lung cancer (NSCLC) is a malignancy that faces serious resistance challenges in treatment. In this study, we identified Piperlongumine as a promising therapeutic candidate to overcome Osimertinib resistance in NSCLC. We systematically investigated the inhibitory effect of Piperlongumine on NSCLC cells and confirmed that it could effectively inhibit the in vitro kinase activity of wild-type (WT), exon 19 deletion, and L858R/T790M-mutated EGFR. We also found that Piperlongumine-induced intrinsic apoptosis by interfering with the EGFR signaling pathway, which was characterized by the down-regulation of the anti-apoptotic protein Mcl-1. Further mechanistic studies revealed that Piperlongumine-induced degradation of Mcl-1 was dependent on the Akt-GSK3β signaling pathway. Additionally, Piperlongumine-promoted interaction between Mcl-1 and β-TRCP, thereby enhancing β-TRCP-mediated ubiquitination and the degradation of Mcl-1. Furthermore, Piperlongumine significantly inhibited tumor growth in both Osimertinib-sensitive and resistant NSCLC xenograft models. These findings highlight the potential of Piperlongumine as an effective agent in overcoming EGFR-targeted therapy resistance and suggest new avenues for its clinical application in NSCLC treatment.